View
228
Download
2
Category
Preview:
Citation preview
EudraVigilance: are you ready for change?
Pharmacovigilance Platform Nederland 26 September 2017
Anja van Haren
1
Content
1.Introduction
2.MAH obligation for signal detection on EV
3.ADR reports
4.Closure
2
Regulation (EU) 1235/2010
Directive 2010/84/EU
EC Implementing Regulation 520/2012
GVP Modules
(Good Pharmacovigilance Practice)
applicable
since July 2012
Pharmacovigilance legislation
3
Changes
Risk management plan
Post Authorisation Safety Studies
PSURs
Meten effecten risk minimisation Bijwerkingen
Signaal detectie
Wetenschappelijke committees /PRAC
Transparantie
Farmacovigilantie master file
Farmacovigilantie inspecties
Referrals union procedures
Additional monitoring
Renewal
Webportals
Worksharing
Literatuur monitoring
Art57 database
ISO IDMP
4
Transitional Provisions
Legal provisions for a transitional period for some of the new requirements: • These could only enter into force after a major upgrade
of EV
Signal detection: - Obligation on MAHs to monitor EV ADR reporting: - Simplified logistics for ADR reporting - Submission of non-serious ADRs from EEA - Use of internationally agreed standards for exchange of
information
5
Transitional Period
6
Dec 2010
Jul 2012
Dec 2013
Feb 2017
22 May 2017
22 Nov 2017
publication of
PhV legislation
EV functional specs agreed
EMA MB announcement
on EV full functionality
most of PhV legislation
applies
independent audit of new EV system
new rules will apply:
end of transitional
period
Content
1.Introduction
2.MAH obligations for signal detection on EV
3.ADR reports
4.Closure
7
Signal detection & management
Implementing Regulation, Art 18 & 21: • obligation on MAHs to monitor EV to the extent that
they have access to the database - with a frequency proportionate to the identified risk, the potential risks and the need for additional information
• MAH shall validate new signals and forthwith inform
EMA and NCAs
Guidance will be provided in Revised Good Vigilance Practice Module IX –Signal Management (expected in Oct 2017)
8
9
Access to EudraVigilance
10
ICSRs in XML format ICSR forms
e-RMRs ICSR line listings ICSR forms
Access to EudraVigilance
> 6 million ICSRs in EV Post Marketing Module
11
Example e-RMR on EMA website
risk-based: at least every 6 months
more frequent for active substances contained in
products under additional monitoring
How to inform authorities?*
Safety variation: - 3 months (important risks) - 6 months (non-important risks)
PSUR (EURD list): - 6 months
Standalone signal notification: - 30 days to EMA/NCAs
Emerging Safety Issue: -3 working days to EMA/NCAs
12 * Pending finalisation of GVP IX
http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000587.jsp&mid=WC0b01ac0580727d1b
13
Signal management pilot
Signal management pilot
Requirement for MAHs to monitor EV data and inform EMA/NCAs of validated signals: • will start on 22 February 2018 • will only apply, for a pilot period of 1 year,
to active substances on additional monitoring list Concerned MAHs have 3 months to familiarise themselves with the EV tools and the new process outlined in GVP IX For other substances, MAHs will still have EV access and will be able to use the data as an additional data source for their existing signal management activities
14
Content
1.Introduction
2.MAH obligations for signal detection on EV
3.ADR reports
4.Closure
15
NCA..1
NCA..2
NCA..28
domestic Non-EU
MAH
domestic
domestic
Old
domestic
domestic
1. Simplified ADR routing
16
NCA..1
NCA..2
NCA..28
MAH
domestic
all
domestic
domestic
ADRs on own
substance
New
1. Simplified ADR routing
17
EEA
Current situation: no obligation to submit non-serious reports to EV
From 22 Nov 2017:
NCAs and MAHs should submit non-serious EEA cases to EV within 90 days
2. Non-serious cases
18
22 Nov
2017
Receipt of ADR
Day 0
Submission
Day 90
Feb
2018
19
Since Nov 2005 ADRs are exchanged electronically using an ICH XML message standard: ICH E2B(R2)
EU legislation requires use of an ISO standard ISO ICSR 27953-2 -ICH issued an implementation guide for using this ISO standard, referred to as ICH E2B(R3)
IT systems are now changing to support E2B(R3), but….
this is not just an IT change!
is also a major business change
3. Use internationally agreed standards
19
20
Different XML message
20
E2B(R3) E2B(R2)
21
– New data-elements
– Data elements have become repeatable (e.g. indication)
– Use of new values for some data elements
– Option to send attachments (publication, pictures, ECG)
– New concept of ‘amendment report’
– Flag to indicate which drug was involved in medication error, overdose, misuse, etc
Examples of changes in R3 (1)
21
22
- Use of different languages
- Information at case level in R2 has moved to event level in R3:
• Seriousness criteria
• Medical confirmation
• Country where the event occurred
22
Examples of changes in R3 (2)
23
variety of possibilities to indicate that information is not available:
Not all null flavours are available for every element
23
New: use of Null flavours
NI = no information MSK = information available but withheld UNK = unknown NA = not applicable ASKU = requested but not provided (by reporter) NASK = not asked
24
Values allowed for ‘age category’
R2 R3
1 = Neonate
2 = Infant
3 = Child
4 = Adolescent
5 = Adult
6 = Elderly
0 = Foetus
1 = Neonate
2 = Infant
3 = Child
4 = Adolescent
5 = Adult
6 = Elderly
Example of a new value
Business impact
Data entry, assessment as well as analysis! No stop date yet for using R2 messages => R2 and R3 will be used in parallel for now When analysing data, be aware: - that database will contain cases submitted under R2 and R3 (e.g. filtering on new value of foetus introduced in R3 will not retrieve any case reported under R2) - impact of conversions on data quality
25
‘ICSR’ form
replaces
old ‘CIOMS’ form
http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2017/0
6/WC500229803.pdf
26
ICSR form
will only appear when data is submitted for that data element
27
28
Content
1.Introduction
2.MAH obligations for signaldetection on EV
3.ADR reports
4.Closure
29
Clinical Trial Regulation
30
In principle no changes to SUSAR reporting process until the application of the Clinical Trial Regulation - 1 change: E2B(R3) format can be used for SUSARs Timing depends on confirmation of full functionality of the EU clinical trial portal and database through an independent audit Expected during 2019 instead of October 2018, as previously scheduled http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000629.jsp&mid=WC0b01ac05808768df
Revised GVP Modules
31
Applicable from 22nd November: GVP Module VI Revision 2 (published July 2017) GVP Module IX Revision 1 to be published Oct 2017
32
EMA training
EV page: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000679.jsp&mid=WC0b01ac05800250b5
EV training page: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/q_and_a/q_and_a_detail_000162.jsp
To conclude…
Big changes ahead of us by November 2017 - uncertain what workload/impact will be
EV changes impact all stakeholders
We need to get familiar with new systems and adapt business processes Training/guidance already available and more coming
33
Thank you for your attention
34
• ADR = Adverse Drug Reaction
• EEA = European Economic Area
• EMA = European Medicines Agency
• EV = EudraVigilance
• E-RMR = Electronic Reaction Monitoring Report
• EVDAS = Eudravigilance Data Analysis System
• GVP = Good Vigilance Practice
• ICH = intenational Council on Harmonisation
• ICSR = Individual Case Safety Report
• IDMP = Identification of Medicinal Products
• MAH = Marketing Authorisation Holder
• NCA = National Competent Authority
• PSUR = Periodic Safety Update Report
• RMP = Risk Management Plan
• WHO= World Health Organisation
Abbreviations
35
Recommended